US6083903A
(en)
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US6838477B2
(en)
*
|
1995-04-12 |
2005-01-04 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
FR2758329B1
(fr)
*
|
1997-01-16 |
1999-02-12 |
Synthelabo |
Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
|
DE69814618T2
(de)
|
1997-02-15 |
2004-03-25 |
Millenium Pharmaceuticals, Inc., Cambridge |
Behandlung von infarkten durch inhibierung von nf-kappab
|
US6221888B1
(en)
*
|
1997-05-29 |
2001-04-24 |
Merck & Co., Inc. |
Sulfonamides as cell adhesion inhibitors
|
CA2304622A1
(en)
*
|
1997-09-25 |
1999-04-01 |
Proscript, Inc. |
Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-?b via the ubiquitin proteasome pathway to treat inflammatory and autoimmunediseases
|
DE69837393T2
(de)
*
|
1997-09-29 |
2007-12-06 |
Point Therapeutics, Inc., Boston |
Stimulierung von hämatopoietischen zellen im vitro
|
US6831057B2
(en)
*
|
1997-10-28 |
2004-12-14 |
The University Of North Carolina At Chapel Hill |
Use of NF-κB inhibition in combination therapy for cancer
|
CA2219867A1
(en)
*
|
1997-10-31 |
1999-04-30 |
Jiangping Wu |
The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
|
DE19802450A1
(de)
*
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
|
US6075150A
(en)
|
1998-01-26 |
2000-06-13 |
Cv Therapeutics, Inc. |
α-ketoamide inhibitors of 20S proteasome
|
US6617171B2
(en)
*
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
FR2779653B1
(fr)
*
|
1998-06-11 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de composes modulateurs du proteasome en therapie
|
US6838436B1
(en)
*
|
1998-07-10 |
2005-01-04 |
Osteoscreen Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6902721B1
(en)
|
1998-07-10 |
2005-06-07 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity for stimulating bone growth
|
US6462019B1
(en)
*
|
1998-07-10 |
2002-10-08 |
Osteoscreen, Inc. |
Inhibitors of proteasomal activity and production for stimulating bone growth
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
EP0982317A1
(en)
*
|
1998-08-26 |
2000-03-01 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Bivalent inhibitors of the proteasome
|
US6613541B1
(en)
*
|
1998-10-20 |
2003-09-02 |
Millennium Pharmaceuticals, Inc. |
Method for monitoring proteasome inhibitor drug action
|
US6492333B1
(en)
|
1999-04-09 |
2002-12-10 |
Osteoscreen, Inc. |
Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
US6649593B1
(en)
*
|
1999-10-13 |
2003-11-18 |
Tularik Inc. |
Modulators of SREBP processing
|
US20040039129A1
(en)
*
|
2000-08-16 |
2004-02-26 |
Hall Dennis G. |
Non-pressurized methods for the preparation of conjugrated solid supports for boronic acids
|
US6919382B2
(en)
|
2000-08-31 |
2005-07-19 |
The Governors Of The University Of Alberta |
Preparation and uses of conjugated solid supports for boronic acids
|
AU2002218133A1
(en)
*
|
2000-10-12 |
2002-04-22 |
Viromics Gmbh |
Agents for the treatment of viral infections
|
PT3078667T
(pt)
*
|
2001-01-25 |
2018-12-28 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Formulação de compostos de ácido borónico
|
US7112588B2
(en)
*
|
2001-05-21 |
2006-09-26 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
CA2447909C
(en)
|
2001-05-21 |
2011-04-05 |
Alcon, Inc. |
Use of proteasome inhibitors to treat dry eye disorders
|
BR0210112A
(pt)
*
|
2001-05-30 |
2004-06-08 |
Novartis Ag |
Derivados do ácido 2-{[n-(2-amino-3-(heteroarila ou arila)propionil)-aminoacil]-amino}-alquilborÈnico
|
WO2003033507A1
(fr)
*
|
2001-10-12 |
2003-04-24 |
Kyorin Pharmaceutical Co., Ltd. |
Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
|
JPWO2003033506A1
(ja)
*
|
2001-10-12 |
2005-02-03 |
杏林製薬株式会社 |
アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
|
JP4412586B2
(ja)
|
2002-01-08 |
2010-02-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
|
WO2003077928A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Ariad Pharmaceuticals, Inc. |
Peptide analogues and uses thereof
|
MXPA04008795A
(es)
*
|
2002-03-13 |
2004-11-26 |
Janssen Pharmaceutica Nv |
Derivados de piperazinilo, piperidinilo y morfolino como novedosos inhibidores de la desacetilasa de histona.
|
EP1485348B1
(en)
*
|
2002-03-13 |
2008-06-11 |
Janssen Pharmaceutica N.V. |
Carbonylamino-derivatives as novel inhibitors of histone deacetylase
|
DE60333260D1
(en)
*
|
2002-03-13 |
2010-08-19 |
Janssen Pharmaceutica Nv |
Histone-deacetylase-inhibitoren
|
US7767679B2
(en)
|
2002-03-13 |
2010-08-03 |
Janssen Pharmaceutica N.V. |
Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
|
AU2003223913A1
(en)
*
|
2002-04-05 |
2003-10-20 |
Viromics Gmbh |
Agents for treating less thanigreater thanflaviviridaeless than/igreater than infections
|
US7514579B2
(en)
*
|
2002-06-13 |
2009-04-07 |
Johns Hopkins University |
Boronic chalcone derivatives and uses thereof
|
US20040077601A1
(en)
*
|
2002-07-09 |
2004-04-22 |
Point Therapeutics, Inc. |
Methods and compositions relating to isoleucine boroproline compounds
|
ES2282658T3
(es)
*
|
2002-08-14 |
2007-10-16 |
Janssen Pharmaceutica N.V. |
Uso de inhibidores de nf-kappa b para el tratamiento de la mastitis.
|
US20050119226A1
(en)
*
|
2003-09-09 |
2005-06-02 |
Trigen Limited |
Methods for synthesizing organoboronic compounds and products thereof
|
EP1466917A1
(en)
*
|
2002-09-09 |
2004-10-13 |
Trigen Limited |
Method for making peptide boronic acids and acids obtainable thereby
|
US20060084592A1
(en)
*
|
2002-09-09 |
2006-04-20 |
Trigen Limited |
Peptide boronic acid inhibitors
|
US7371729B2
(en)
*
|
2002-09-09 |
2008-05-13 |
Trigen Limited |
Boronic acid salts useful in parenteral formulations
|
US20050282757A1
(en)
*
|
2002-09-09 |
2005-12-22 |
Trigen Limited |
Peptide boronic acid compounds useful in anticoagulation
|
US20050176651A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Trigen Limited |
Peptide boronic acids useful in making salts thereof
|
EP1542768A1
(en)
*
|
2002-09-20 |
2005-06-22 |
Alcon, Inc. |
Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
|
AU2003298873B2
(en)
|
2002-12-06 |
2011-09-01 |
Millennium Pharmaceuticals, Inc. |
Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
|
CN100341880C
(zh)
*
|
2003-02-13 |
2007-10-10 |
上海仁虎制药股份有限公司 |
新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
|
WO2005007211A2
(en)
*
|
2003-07-03 |
2005-01-27 |
Medtronic Vascular Inc. |
Medical devices with proteasome inhibitors for the treatment of restenosis
|
US7576206B2
(en)
*
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
*
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
CN1878568A
(zh)
|
2003-11-05 |
2006-12-13 |
盘林京有限公司 |
Cdim结合抗体的增强的b细胞细胞毒性
|
US20060052390A1
(en)
*
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
WO2005082348A2
(en)
*
|
2004-02-23 |
2005-09-09 |
Trustees Of Tufts College |
Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
|
GB0405272D0
(en)
*
|
2004-03-09 |
2004-04-21 |
Trigen Ltd |
Compounds
|
US7371875B2
(en)
*
|
2004-03-12 |
2008-05-13 |
Miikana Therapeutics, Inc. |
Cytotoxic agents and methods of use
|
HRP20240307T3
(hr)
*
|
2004-03-30 |
2024-05-10 |
Millennium Pharmaceuticals, Inc. |
Sinteza spojeva estera borne kiseline i kiseline
|
AU2016202747B2
(en)
*
|
2004-03-30 |
2017-11-23 |
Millennium Pharmaceuticals, Inc. |
Synthesis of boronic ester and acid compounds
|
US8198270B2
(en)
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
PT1745064E
(pt)
|
2004-04-15 |
2011-03-23 |
Proteolix Inc |
Compostos para a inibição de uma enzima de proteassoma
|
BRPI0510802A
(pt)
|
2004-05-10 |
2007-11-06 |
Proteolix Inc |
compostos para inibição de enzima
|
EP2277595A3
(en)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
CN101087756B
(zh)
|
2004-07-23 |
2011-04-06 |
纽阿达有限责任公司 |
肽酶抑制剂
|
PL1781639T3
(pl)
|
2004-07-28 |
2012-07-31 |
Janssen Pharmaceutica Nv |
Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
|
EP2100899A3
(en)
|
2004-10-20 |
2009-09-30 |
Proteolix, Inc. |
Compounds for proteasome enzyme inhibition
|
JP2008519030A
(ja)
|
2004-11-05 |
2008-06-05 |
パリンゲン インコーポレーテッド |
抗体で誘導される細胞膜損傷
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
US8017395B2
(en)
|
2004-12-17 |
2011-09-13 |
Lifescan, Inc. |
Seeding cells on porous supports
|
US20070098685A1
(en)
*
|
2005-01-19 |
2007-05-03 |
Brand Stephen J |
Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
US20090018146A1
(en)
*
|
2005-01-27 |
2009-01-15 |
Research Development Corporation |
Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
|
US7468383B2
(en)
*
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
DK2987796T3
(en)
|
2005-02-16 |
2018-09-17 |
Anacor Pharmaceuticals Inc |
HALOGEN-SUBSTITUTED BORONOPHTHALIDES FOR TREATING INFECTIONS
|
EP1863513A2
(en)
*
|
2005-03-11 |
2007-12-12 |
The University of North Carolina at Chapel Hill |
Potent and specific immunoproteasome inhibitors
|
EP1874297A4
(en)
*
|
2005-04-29 |
2009-04-22 |
Kosan Biosciences Inc |
METHOD OF TREATING MULTIPLE MYELOMES USING 17AGENE OR 17-AG OR A PRODRUG OR ALL IN COMBINATION WITH A PROTEASOMIC INHIBITOR
|
EP1885710B1
(en)
|
2005-05-18 |
2015-08-19 |
Janssen Pharmaceutica N.V. |
Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
|
AU2006202209B2
(en)
*
|
2005-05-27 |
2011-04-14 |
Lifescan, Inc. |
Amniotic fluid derived cells
|
PT1888123E
(pt)
*
|
2005-06-08 |
2013-03-13 |
Janssen Biotech Inc |
Uma terapêutica celular para a degeneração ocular
|
US20090017006A1
(en)
*
|
2005-07-06 |
2009-01-15 |
Biodevelops Pharma Entwicklung Gmbh |
Use of a compound for enhancing the expression of membrane proteins on the cell surface
|
EP1752467A1
(en)
|
2005-08-10 |
2007-02-14 |
4Sc Ag |
Inhibitors of cancer cell, t-cell and keratinocyte proliferation
|
US7531517B2
(en)
|
2005-08-10 |
2009-05-12 |
4Sc Ag |
Inhibitors of cancer cell, T-cell and keratinocyte proliferation
|
US20070059382A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Board Of Regents, Univ. And Comm. College System Of Nevada... |
Medical treatment of breast cancer with boric acid materials
|
NZ595196A
(en)
|
2005-11-09 |
2013-03-28 |
Proteolix Inc |
Peptide-based compounds for enzyme inhibition
|
EP1956908A2
(en)
*
|
2005-12-08 |
2008-08-20 |
Cytokinetics, Inc. |
Certain compositions and methods of treatment
|
BRPI0621279B1
(pt)
|
2005-12-30 |
2021-07-20 |
Anacor Pharmaceuticals, Inc |
Moléculas pequenas contendo boro
|
RS51191B
(sr)
*
|
2006-01-19 |
2010-10-31 |
Janssen Pharmaceutica N.V. |
Derivati aminofenila kao novi inhibitori histon deacetilaze
|
CA2631874C
(en)
*
|
2006-01-19 |
2014-11-18 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
CA2635015C
(en)
*
|
2006-01-19 |
2014-06-03 |
Janssen Pharmaceutica N.V. |
Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
|
AU2007206942B2
(en)
|
2006-01-19 |
2012-08-23 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
KR20150013941A
(ko)
|
2006-02-16 |
2015-02-05 |
아나코르 파마슈티칼스 인코포레이티드 |
항염증제로서 보론함유 소분자
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US8741643B2
(en)
*
|
2006-04-28 |
2014-06-03 |
Lifescan, Inc. |
Differentiation of pluripotent stem cells to definitive endoderm lineage
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
US7691852B2
(en)
|
2006-06-19 |
2010-04-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
AU2007296259A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Janssen Pharmaceutica Nv |
Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors
|
MX2009002925A
(es)
*
|
2006-09-15 |
2009-03-31 |
Janssen Pharmaceutica Nv |
Inhibidores de histona desacetilasa con actividad combinada sobre histona desacetilasas clase i y clase iib en combinacion con inhibidores del proteasoma.
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
AU2007221966A1
(en)
*
|
2006-12-08 |
2008-06-26 |
Centenary Institute Of Cancer Medicine And Cell Biology |
Assay for response to proteasome inhibitors
|
JO3396B1
(ar)
|
2007-06-20 |
2019-10-20 |
Anacor Pharmaceuticals Inc |
جزيئات صغيرة تحتوي على البورون
|
US9080145B2
(en)
*
|
2007-07-01 |
2015-07-14 |
Lifescan Corporation |
Single pluripotent stem cell culture
|
CN101952415B
(zh)
|
2007-07-31 |
2017-06-27 |
生命扫描有限公司 |
人胚胎干细胞的分化
|
JP2010535708A
(ja)
|
2007-08-03 |
2010-11-25 |
ビオマリン アイジーエー リミテッド |
デュシェンヌ型筋ジストロフィーの治療のための薬物併用
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
AU2016253697A1
(en)
*
|
2007-08-06 |
2016-11-24 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US7442830B1
(en)
*
|
2007-08-06 |
2008-10-28 |
Millenium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
PL2178888T3
(pl)
*
|
2007-08-06 |
2012-11-30 |
Millennium Pharm Inc |
Inhibitory proteasomów
|
EA034601B1
(ru)
*
|
2007-08-06 |
2020-02-25 |
Милленниум Фармасьютикалз, Инк. |
Способ получения бороновых кислот
|
WO2009036281A2
(en)
*
|
2007-09-12 |
2009-03-19 |
Dr. Reddy's Laboratories Ltd. |
Bortezomib and process for producing same
|
US20090076031A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched bortezomib
|
SG10201902704TA
(en)
|
2007-10-04 |
2019-04-29 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
US7838673B2
(en)
*
|
2007-10-16 |
2010-11-23 |
Millennium Pharmaceuticals, Inc. |
Proteasome inhibitors
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
CA2706560C
(en)
|
2007-11-27 |
2017-02-28 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells to pancreatic cells
|
CN101220048B
(zh)
*
|
2007-12-14 |
2012-08-15 |
江苏先声药物研究有限公司 |
ZnCl2催化下的蒎烷二醇酯的制备方法
|
AR069798A1
(es)
|
2007-12-20 |
2010-02-17 |
Novartis Ag |
Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
|
CN102046779A
(zh)
|
2008-02-21 |
2011-05-04 |
森托科尔奥索生物科技公司 |
用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
|
CA2718170A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-inflammatory agents
|
US20100256092A1
(en)
*
|
2008-05-12 |
2010-10-07 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
EA030685B1
(ru)
*
|
2008-06-17 |
2018-09-28 |
Милленниум Фармасьютикалз, Инк. |
Способ получения соединения боронатного эфира
|
MX2011000125A
(es)
|
2008-06-30 |
2011-02-25 |
Centocor Ortho Biotech Inc |
Diferenciacion de celulas madre pluripotentes.
|
CN101638414B
(zh)
*
|
2008-07-30 |
2014-01-08 |
江苏先声药物研究有限公司 |
肽硼酸及其酯类化合物、制备方法及其用途
|
US20100028307A1
(en)
*
|
2008-07-31 |
2010-02-04 |
O'neil John J |
Pluripotent stem cell differentiation
|
EP2348863A4
(en)
*
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
WO2010028005A1
(en)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
AR075090A1
(es)
|
2008-09-29 |
2011-03-09 |
Millennium Pharm Inc |
Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
|
WO2010045503A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as anti-protozoal agents
|
EP3090737A1
(en)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Combination therapy with peptide epoxyketones
|
MX349178B
(es)
*
|
2008-10-31 |
2017-07-17 |
Centocor Ortho Biotech Inc |
Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
|
PL2346988T3
(pl)
|
2008-10-31 |
2017-10-31 |
Janssen Biotech Inc |
Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki
|
CN102257132B
(zh)
*
|
2008-11-20 |
2014-09-03 |
森托科尔奥索生物科技公司 |
用于在平面基底上进行细胞附着和培养的方法和组合物
|
MX2011005288A
(es)
|
2008-11-20 |
2011-06-01 |
Centocor Ortho Biotech Inc |
Celulas madre pluripotentes en microportadores.
|
CN101747354B
(zh)
*
|
2008-12-04 |
2014-08-13 |
江苏先声药物研究有限公司 |
一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
|
CN102256494A
(zh)
*
|
2008-12-17 |
2011-11-23 |
阿纳科制药公司 |
(s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
|
MX2011007192A
(es)
|
2009-01-09 |
2011-10-04 |
Sun Pharma Advanced Res Co Ltd |
Composicion farmaceutica.
|
EP2399129B1
(en)
|
2009-02-20 |
2015-11-25 |
Michael P. Lisanti |
A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
|
KR101781654B1
(ko)
|
2009-03-12 |
2017-09-25 |
제넨테크, 인크. |
조혈 악성종양의 치료를 위한 포스포이노시티드 3-키나제 억제제 화합물 및 화학요법제의 조합물
|
WO2010106135A1
(en)
|
2009-03-20 |
2010-09-23 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Combined use for the treatment of ovarian carcinoma
|
TWI504598B
(zh)
|
2009-03-20 |
2015-10-21 |
Onyx Therapeutics Inc |
結晶性三肽環氧酮蛋白酶抑制劑
|
AU2010229988B9
(en)
*
|
2009-03-24 |
2015-09-17 |
Janssen Pharmaceutica Nv |
Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
WO2010114768A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-epothilone conjugates, particles, compositions, and related methods of use
|
CA2756072A1
(en)
*
|
2009-03-30 |
2010-10-14 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
CA2763471A1
(en)
*
|
2009-05-27 |
2010-12-02 |
Cephalon, Inc. |
Combination therapy for the treatment of multiple myeloma
|
CN102803271B
(zh)
|
2009-06-19 |
2016-03-23 |
力奇制药公司 |
氢化卤代烯烃而不脱卤的方法
|
CN101928329B
(zh)
*
|
2009-06-19 |
2013-07-17 |
北京大学 |
三肽硼酸(酯)类化合物、其制备方法和应用
|
EP2270019A1
(en)
|
2009-06-19 |
2011-01-05 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters
|
EP2280016A1
(en)
|
2009-07-27 |
2011-02-02 |
LEK Pharmaceuticals d.d. |
New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
DE102009027754A1
(de)
|
2009-07-15 |
2011-05-05 |
Schubert, Ulrich, Dr. |
Verfahren zur Hemmung der Reifung von dendritischen Zellen
|
RU2540021C2
(ru)
*
|
2009-07-20 |
2015-01-27 |
Янссен Байотек, Инк. |
Дифференцировка эмбриональных стволовых клеток человека
|
MX2012000898A
(es)
|
2009-07-20 |
2012-06-01 |
Janssen Biotech Inc |
Diferenciacion de celulas madre embrionarias humanas.
|
WO2011011300A2
(en)
|
2009-07-20 |
2011-01-27 |
Centocor Ortho Biotech Inc. |
Differentiation of human embryonic stem cells
|
KR20130031233A
(ko)
*
|
2009-07-28 |
2013-03-28 |
아나코르 파마슈티칼스 인코포레이티드 |
삼치환된 붕소 함유 분자
|
WO2011019618A1
(en)
|
2009-08-14 |
2011-02-17 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
WO2011022502A1
(en)
|
2009-08-18 |
2011-02-24 |
Georgetown University |
Boronic acid compositions and methods related to cancer
|
WO2011022337A1
(en)
*
|
2009-08-19 |
2011-02-24 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
EP2475659B1
(en)
|
2009-09-08 |
2015-10-28 |
F.Hoffmann-La Roche Ag |
4-substituted pyridin-3-yl-carboxamide compounds and methods of use
|
US20110124597A1
(en)
*
|
2009-09-25 |
2011-05-26 |
Anacor Pharmaceuticals, Inc. |
Boron containing small molecules
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2519231B1
(en)
*
|
2009-10-01 |
2017-03-15 |
Janssen Pharmaceutica NV |
Proteasome inhibitors for treating cancer
|
WO2011049971A1
(en)
|
2009-10-20 |
2011-04-28 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules as antiprotozoal agents
|
US8461134B2
(en)
*
|
2009-11-11 |
2013-06-11 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
JP5919196B2
(ja)
|
2009-11-13 |
2016-05-18 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
転移抑制のためのペプチドエポキシケトンの使用
|
NZ600786A
(en)
*
|
2009-12-22 |
2013-12-20 |
Cephalon Inc |
Proteasome inhibitors and processes for their preparation, purification and use
|
US9150833B2
(en)
|
2009-12-23 |
2015-10-06 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
JP5882226B2
(ja)
|
2009-12-23 |
2016-03-09 |
ヤンセン バイオテツク,インコーポレーテツド |
ヒト胚性幹細胞の分化
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
US8716478B2
(en)
|
2010-01-27 |
2014-05-06 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
JP6013196B2
(ja)
|
2010-03-01 |
2016-10-25 |
ヤンセン バイオテツク,インコーポレーテツド |
多能性幹細胞から誘導した細胞を精製するための方法
|
SG183843A1
(en)
*
|
2010-03-01 |
2012-10-30 |
Onyx Therapeutics Inc |
Compounds for immunoproteasome inhibition
|
NZ602392A
(en)
*
|
2010-03-18 |
2014-03-28 |
Innopharma Inc |
Stable bortezomib formulations
|
US8263578B2
(en)
|
2010-03-18 |
2012-09-11 |
Innopharma, Inc. |
Stable bortezomib formulations
|
AP2012006482A0
(en)
|
2010-03-19 |
2012-10-31 |
Anacor Pharmacueticals Inc |
Boron-containing small molecules as anti-protozoalagent
|
AU2011230619C1
(en)
|
2010-03-25 |
2016-06-23 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
UA110612C2
(uk)
*
|
2010-03-31 |
2016-01-25 |
Мілленніум Фармасьютікалз, Інк. |
Похідні 1-аміно-2-циклопропілетилборонової кислоти
|
AU2013204868B2
(en)
*
|
2010-03-31 |
2016-10-13 |
Millennium Pharmaceuticals, Inc. |
Derivatives of 1-amino-2-cyclopropylethylboronic acid
|
JP2013525282A
(ja)
|
2010-04-07 |
2013-06-20 |
オニキス セラピューティクス, インク. |
結晶質ペプチドエポキシケトンイムノプロテアソーム阻害剤
|
CN101812026B
(zh)
*
|
2010-04-12 |
2013-08-28 |
亚邦医药股份有限公司 |
一种硼替佐米的合成方法
|
EP2560647B1
(en)
|
2010-04-19 |
2016-04-13 |
Niiki Pharma Inc. |
Combination therapy with a proteasome inhibitor and a gallium complex
|
US8809282B2
(en)
|
2010-05-06 |
2014-08-19 |
Duke University |
Method of reducing titers of antibodies specific for a therapeutic agent
|
RU2587634C2
(ru)
|
2010-05-12 |
2016-06-20 |
Янссен Байотек, Инк. |
Дифференцирование эмбриональных стволовых клеток человека
|
EA035193B1
(ru)
|
2010-05-18 |
2020-05-14 |
Серулин Фарма Инк. |
Композиции и способы лечения аутоиммунных и других заболеваний
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
EP2853589B1
(en)
|
2010-08-31 |
2017-12-27 |
Janssen Biotech, Inc. |
Differentiation of human embryonic stem cells
|
US9181528B2
(en)
|
2010-08-31 |
2015-11-10 |
Janssen Biotech, Inc. |
Differentiation of pluripotent stem cells
|
MX355340B
(es)
|
2010-08-31 |
2018-04-16 |
Janssen Biotech Inc |
Diferenciación de células madre embrionarias humanas.
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
RS62548B1
(sr)
|
2010-09-07 |
2021-12-31 |
Anacor Pharmaceuticals Inc |
Derivati benzoksaborola za lečenje bakterijskih infekcija
|
US8962572B2
(en)
|
2010-10-05 |
2015-02-24 |
Fresenius Kabi Usa, Llc |
Bortezomib formulations
|
WO2012048745A1
(en)
|
2010-10-14 |
2012-04-19 |
Synthon Bv |
Process for making bortezomib and intermediates for the process
|
WO2012104776A1
(en)
|
2011-01-31 |
2012-08-09 |
Novartis Ag |
Novel heterocyclic derivatives
|
TW201309303A
(zh)
|
2011-03-03 |
2013-03-01 |
Cephalon Inc |
用於治療狼瘡的蛋白酶體抑制劑
|
US9272014B2
(en)
|
2011-03-29 |
2016-03-01 |
Texas Tech University System |
Galectin-3C combination therapy for human cancer
|
CN103502319B
(zh)
|
2011-03-31 |
2015-11-25 |
那野伽利阿株式会社 |
包含含有硼酸化合物的嵌段共聚物的医药组合物
|
EP2691530B1
(en)
|
2011-06-10 |
2018-03-07 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
JP5944986B2
(ja)
*
|
2011-06-22 |
2016-07-05 |
セファロン、インク. |
プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス
|
US8481655B2
(en)
|
2011-07-27 |
2013-07-09 |
Wacker Chemical Corporation |
Copper complexes of amino-functional organosilicon compounds and their use
|
WO2013021032A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
|
WO2013022935A1
(en)
|
2011-08-11 |
2013-02-14 |
Janssen Pharmaceutica Nv |
Predictors for cancer treatment
|
US8927593B2
(en)
|
2011-08-19 |
2015-01-06 |
Glaxo Group Limited |
Benzofuran compounds for the treatment of hepatitis C virus infections
|
PT2753334T
(pt)
*
|
2011-08-30 |
2022-11-03 |
Tufts College |
Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
WO2013063481A1
(en)
|
2011-10-28 |
2013-05-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to nae inhibitors
|
EA023935B1
(ru)
|
2011-10-28 |
2016-07-29 |
Новартис Аг |
Производные пурина и их применение для лечения заболевания
|
US20150184246A1
(en)
|
2011-11-11 |
2015-07-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
CA2855356A1
(en)
|
2011-11-11 |
2013-05-16 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
KR101912978B1
(ko)
|
2011-11-17 |
2018-10-29 |
도꾜 다이가꾸 |
페닐보론산기가 도입된 블록 공중합체 및 그의 용도
|
BR112014015417A8
(pt)
|
2011-12-22 |
2017-07-04 |
Janssen Biotech Inc |
diferenciação de células-tronco embrionárias humanas em células positivas de insulina hormonal únicas
|
WO2013110005A1
(en)
|
2012-01-18 |
2013-07-25 |
Wisconsin Alumni Research Foundation |
Boronate-mediated delivery of molecules into cells
|
US9732101B2
(en)
|
2012-01-18 |
2017-08-15 |
Wisconsin Alumni Research Foundation |
Bioreversible boronates for delivery of molecules into cells
|
US20160008382A1
(en)
|
2012-01-24 |
2016-01-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
WO2013112881A1
(en)
|
2012-01-27 |
2013-08-01 |
Thomas Jefferson University |
Mct protein inhibitor-related prognostic and therapeutic methods
|
IN2014MN01781A
(xx)
|
2012-02-08 |
2015-07-03 |
Igm Biosciences Inc |
|
EP2819673B1
(en)
|
2012-03-02 |
2016-09-07 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions comprising boronic acid compounds
|
SG11201405052RA
(en)
|
2012-03-07 |
2014-10-30 |
Janssen Biotech Inc |
Defined media for expansion and maintenance of pluripotent stem cells
|
CA2784240C
(en)
|
2012-03-27 |
2014-07-08 |
Innopharma, Inc. |
Stable bortezomib formulations
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
DK3450542T3
(da)
|
2012-06-08 |
2021-11-01 |
Janssen Biotech Inc |
Differentiering af humane embryonale stamceller til endokrine pancreatiske celler
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
JP2015524394A
(ja)
|
2012-07-09 |
2015-08-24 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
|
JP2013006855A
(ja)
*
|
2012-09-03 |
2013-01-10 |
Millennium Pharmaceuticals Inc |
プロテアソーム阻害剤
|
BR112015005343A2
(pt)
*
|
2012-09-11 |
2017-07-04 |
Cipla Ltd |
processo para a preparação de bortezomib, composto, bortezomib ou seu anidrido, e, processo para a preparação de um composto
|
CA2886783A1
(en)
|
2012-10-01 |
2014-04-10 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
WO2014072985A1
(en)
|
2012-11-06 |
2014-05-15 |
Natco Pharma Limited |
Novel boronic acid derivatives as anti cancer agents
|
AU2013346322B2
(en)
|
2012-11-16 |
2016-11-10 |
Shilpa Medicare Limited |
Crystalline Bortezomib process
|
WO2014097306A1
(en)
|
2012-12-21 |
2014-06-26 |
Natco Pharma Limited |
Stable and pure polymorphic form of bortezomib
|
CN105705634A
(zh)
|
2012-12-31 |
2016-06-22 |
詹森生物科技公司 |
用于分化成胰腺内分泌细胞的人多能细胞的悬浮和群集
|
MX2015008578A
(es)
|
2012-12-31 |
2015-09-07 |
Janssen Biotech Inc |
Diferenciacion de celulas madre embrionarias humanas en celulas endocrinas pancreaticas mediante el uso de relugadores de hb9.
|
US10370644B2
(en)
|
2012-12-31 |
2019-08-06 |
Janssen Biotech, Inc. |
Method for making human pluripotent suspension cultures and cells derived therefrom
|
SG11201505128SA
(en)
|
2012-12-31 |
2015-07-30 |
Janssen Biotech Inc |
Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
|
CA2905751A1
(en)
|
2013-03-13 |
2014-10-09 |
Forma Therapeutics, Inc. |
Novel compounds and compositions for inhibition of fasn
|
IN2013MU01431A
(xx)
|
2013-04-16 |
2015-06-26 |
Cipla Ltd |
|
US10022372B2
(en)
|
2013-04-19 |
2018-07-17 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2015003146A1
(en)
|
2013-07-03 |
2015-01-08 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
KR20160058886A
(ko)
|
2013-10-03 |
2016-05-25 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
전신 홍반성 낭창 및/또는 낭창성 신염의 예방 또는 치료 방법
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
CN104586776B
(zh)
*
|
2013-10-30 |
2017-05-17 |
扬子江药业集团上海海尼药业有限公司 |
以硼替佐米为活性成分的制剂及其制备方法
|
WO2015076359A1
(ja)
*
|
2013-11-21 |
2015-05-28 |
国立大学法人北海道大学 |
プロテアソーム阻害性化合物
|
EP3077823B1
(en)
|
2013-12-05 |
2019-09-04 |
The Broad Institute, Inc. |
Compositions and methods for identifying and treating cachexia or pre-cachexia
|
ES2899167T3
(es)
|
2013-12-06 |
2022-03-10 |
Novartis Ag |
Régimen posológico para un inhibidor de fosfatidilinositol 3-cinasas selectivo para la isoforma alfa
|
US10167311B2
(en)
|
2014-02-03 |
2019-01-01 |
Ohio State Innovation Foundation |
Boronic acid esters and pharmaceutical formulations thereof
|
EP2910557A1
(en)
*
|
2014-02-20 |
2015-08-26 |
Ikerchem, S.L. |
Enantiopure tetrasubstituted pyrrolidines as scaffolds for proteasome inhibitors and medicinal applications thereof
|
JP6566936B2
(ja)
|
2014-05-08 |
2019-08-28 |
国立大学法人 東京大学 |
医薬組成物
|
CA2949056A1
(en)
|
2014-05-16 |
2015-11-19 |
Janssen Biotech, Inc. |
Use of small molecules to enhance mafa expression in pancreatic endocrine cells
|
JP2017524652A
(ja)
|
2014-05-20 |
2017-08-31 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
|
US10301273B2
(en)
|
2014-08-07 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
CN107074885B
(zh)
*
|
2014-10-01 |
2020-11-27 |
默克专利股份公司 |
硼酸衍生物
|
WO2016110870A1
(en)
|
2015-01-07 |
2016-07-14 |
Emcure Pharmaceuticals Limited |
Pharmaceutical composition of bortezomid
|
MA41505A
(fr)
|
2015-02-11 |
2017-12-19 |
Millennium Pharm Inc |
Nouvelle forme cristalline d'un inhibiteur de protéasome
|
JP2018510859A
(ja)
|
2015-03-17 |
2018-04-19 |
レオン−ナノドラッグズ ゲーエムベーハー |
安定化されたボロン酸化合物を含むナノ粒子
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
WO2016184793A1
(en)
|
2015-05-15 |
2016-11-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
|
US10144761B2
(en)
|
2015-06-19 |
2018-12-04 |
Hanlin Scientific Inc. |
Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
|
EP3120836A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Gebrauchsfertige bortezomib-lösung
|
EP3120837A1
(de)
|
2015-07-22 |
2017-01-25 |
Stada Arzneimittel Ag |
Verfahren zur herstellung einer bortezomibester-lösung
|
CN106478700B
(zh)
*
|
2015-08-26 |
2020-12-29 |
杭州雷索药业有限公司 |
硼基取代的苯胺类蛋白激酶抑制剂
|
CN106588965A
(zh)
*
|
2015-10-15 |
2017-04-26 |
北京大学 |
脲拟肽硼酸化合物及其药物组合物、制备方法和用途
|
EP3370719A1
(en)
|
2015-11-02 |
2018-09-12 |
Novartis AG |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
EP3389715A4
(en)
|
2015-12-14 |
2019-06-12 |
David K. Thomas |
COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION
|
CN107151255A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
硼酸类化合物及其制备方法和用途
|
CN107151254A
(zh)
*
|
2016-03-06 |
2017-09-12 |
复旦大学 |
一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
|
MA45479A
(fr)
|
2016-04-14 |
2019-02-20 |
Janssen Biotech Inc |
Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
|
US11447506B2
(en)
|
2016-05-09 |
2022-09-20 |
Anacor Pharmaceuticals, Inc. |
Crystal forms of crisaborole in free form and preparation method and use thereof
|
CN106008572B
(zh)
*
|
2016-05-23 |
2018-08-17 |
成都千禧莱医药科技有限公司 |
一类二肽硼酸化合物及制备方法和用途
|
BR112018076614A2
(pt)
|
2016-06-21 |
2019-04-02 |
Orion Ophthalmology LLC |
derivados heterocíclicos de prolinamida
|
EP3472151A4
(en)
|
2016-06-21 |
2020-03-04 |
Orion Ophthalmology LLC |
CARBOCYCLIC PROLINAMIDE DERIVATIVES
|
JP6681284B2
(ja)
*
|
2016-06-23 |
2020-04-15 |
信越化学工業株式会社 |
糖アルコール化合物の金属低減方法
|
JP6223508B2
(ja)
*
|
2016-06-27 |
2017-11-01 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
WO2018038687A1
(en)
|
2016-08-22 |
2018-03-01 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
JP2020500839A
(ja)
|
2016-10-20 |
2020-01-16 |
ファイザー・インク |
ペプチドボロン酸またはボロン酸エステル化合物を有する治療用粒子ならびにその作製および使用方法
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
JP2020507615A
(ja)
|
2017-02-17 |
2020-03-12 |
フレゼニウス・カビ・オンコロジー・リミテッド |
ボロン酸エステルの調製のための改良プロセス
|
CA3054572A1
(en)
|
2017-02-28 |
2018-09-07 |
Mayo Foundation For Medical Education And Research |
Compounds and methods for treating cancer
|
CN111601597B
(zh)
|
2017-08-23 |
2023-10-13 |
科智生命科学公司 |
自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
|
BR112020005079A2
(pt)
|
2017-09-14 |
2020-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
tratamento de combinação para câncer
|
JP2018024694A
(ja)
*
|
2017-10-03 |
2018-02-15 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害剤
|
ES2928787T3
(es)
*
|
2017-11-16 |
2022-11-22 |
Principia Biopharma Inc |
Inhibidores del inmunoproteasoma
|
KR102625984B1
(ko)
|
2017-11-16 |
2024-01-18 |
프린시피아 바이오파마, 인코퍼레이티드 |
면역프로테아좀 억제제
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
CN112004537A
(zh)
|
2018-01-09 |
2020-11-27 |
穿梭药业公司 |
用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
|
JP2021512165A
(ja)
|
2018-01-29 |
2021-05-13 |
コグノス・セラピューティクス・インコーポレイテッド |
ボルテゾミブの腫瘍内送達
|
WO2019178438A1
(en)
|
2018-03-15 |
2019-09-19 |
Abbvie Inc. |
Abbv-621 in combination with anti-cancer agents for the treatment of cancer
|
US11243207B2
(en)
|
2018-03-29 |
2022-02-08 |
Mayo Foundation For Medical Education And Research |
Assessing and treating cancer
|
US10793554B2
(en)
|
2018-10-29 |
2020-10-06 |
Forma Therapeutics, Inc. |
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
CN109824756B
(zh)
*
|
2019-03-19 |
2022-03-22 |
山东大学 |
含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
|
CN114437119B
(zh)
*
|
2020-10-30 |
2024-08-09 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白抑制剂及其制备方法和用途
|
JP2023553011A
(ja)
*
|
2020-12-02 |
2023-12-20 |
ホフマン・テクノロジーズ・エルエルシー |
非ヒト哺乳動物においてがんを調節するための組成物および方法
|
TW202237143A
(zh)
*
|
2020-12-10 |
2022-10-01 |
南韓商Lg化學股份有限公司 |
酸(Boronic Acid)化合物
|
US11964993B2
(en)
|
2021-07-03 |
2024-04-23 |
Shilpa Pharma Lifesciences Limited |
Crystalline bortezomib process
|
EP4134083A1
(en)
|
2021-08-12 |
2023-02-15 |
Extrovis AG |
Pharmaceutical compositions of bortezomib
|
CN113957441B
(zh)
*
|
2021-10-29 |
2024-01-02 |
光华科学技术研究院(广东)有限公司 |
蚀刻液及其制备方法和应用
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|